A5016979524- Obstructive Sleep Apnea Research
- Neuroscience of respiration and sleep
- Respiratory Support and Mechanisms
- Cardiovascular and Diving-Related Complications
- Cardiovascular Syncope and Autonomic Disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Tracheal and airway disorders
- Extracellular vesicles in disease
- Sleep and related disorders
- Sleep and Wakefulness Research
- Cystic Fibrosis Research Advances
- High Altitude and Hypoxia
- Cardiovascular Health and Disease Prevention
- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Dysphagia Assessment and Management
- Asthma and respiratory diseases
- Botulinum Toxin and Related Neurological Disorders
- Inflammatory Myopathies and Dermatomyositis
- Diet and metabolism studies
- Pediatric health and respiratory diseases
- Cardiovascular Disease and Adiposity
- Pneumonia and Respiratory Infections
- Neonatal Respiratory Health Research
- Eosinophilic Disorders and Syndromes
Université d'Angers
2014-2025
Centre National de la Recherche Scientifique
2009-2024
Centre Hospitalier Universitaire d'Angers
2014-2024
Inserm
2013-2024
Centre Hospitalier René-Dubos
2024
Laboratoire Stress Oxydant et Pathologies Métaboliques
2009-2020
Université Bretagne Loire
2016-2019
Université de Poitiers
2019
Université Nantes Angers Le Mans
2012-2013
Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in and advanced respiratory disease. Methods: A prospective observational study, including all aged ⩾12 years percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August...
Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they carry F508del allele on CF transmembrane conductance regulator (CFTR) gene. Considering that pwCF carrying rare variants may benefit from ETI, including already validated by US Food and Drug Administration (FDA), a compassionate use programme was launched France. PwCF were invited undergo nasal brushing investigate whether pharmacological...
Rationale: Limited data exist on safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) advanced lung disease. Objective: To evaluate the effects ETI an unselected population pwCF Methods: A prospective observational study, including all adults, aged 18 years older, a percent predicted FEV1 (ppFEV1)≤ 40 who initiated from December 2019 to June 2021 France was conducted. PwCF were followed until August 8th, 2022. Results: 434 median...
We tested the hypothesis of an independent cross-sectional association between obstructive sleep apnea (OSA) severity and glycated hemoglobin (HbA(1c)) in adults without known diabetes.HbA(1c) was measured whole-blood samples from 2,139 patients undergoing nocturnal recording for suspected OSA. Participants with self-reported diabetes, use diabetes medication, or HbA(1c) value ≥6.5% were excluded this study. Our final sample size comprised 1,599 patients.A dose-response relationship observed...
Rationale: Endothelial dysfunction, a major predictor of late cardiovascular events, is linked to the severity obstructive sleep apnea (OSA).Objectives: To determine whether treatment with mandibular advancement device, main alternative continuous positive airway pressure, improves endothelial function in patients severe OSA.Methods: In this trial, we randomized OSA and no overt disease receive 2 months either effective device or sham device. The primary outcome, change reactive hyperemia...
Obstructive sleep apnea (OSA) and short duration are individually associated with an increased risk for hypertension (HTN). The aim of this multicenter cross-sectional study was to test the hypothesis a cumulative association OSA severity prevalent HTN. Among 1,499 patients undergoing polysomnography suspected OSA, 410 (27.3%) previously diagnosed as hypertensive taking antihypertensive medication were considered having Patients total time (TST) <6 h be sleepers. Logistic regression...
To assess, in a large cohort of patients with obstructive sleep apnea, the factors that are independently associated positional apnea (POSA) and exclusive POSA (e-POSA) determine their prevalence. The secondary objective was to evaluate outcome positive airway pressure (PAP) therapy for e-POSA.This retrospective study included 6,437 typical mild-to-severe OSA from Pays de la Loire cohort. Patients e-POSA were compared those non-POSA clinical polysomnographic characteristics. In subgroup (n =...
Sleep-disordered breathing (SDB) is a common comorbidity in patients with heart failure (HF) and associated worse prognosis.
Non-invasive ventilation (NIV) is the reference treatment for chronic respiratory failure (CRF) due to impairment of ventilatory system. Home initiation increasingly practiced. To better support this ambulatory shift, we aimed assess implementation constraints and short-term efficacy according different aetiologies CRF. This retrospective study with cross-sectional longitudinal analysis included patients initiated NIV at Angers University Hospital. Patients were separated following...
Summary The purpose of this study was to determine whether the association between obstructive sleep apnea severity and glucose control differs patients with newly diagnosed untreated type 2 diabetes, known treated diabetes. This multicentre cross‐sectional included 762 investigated by recording for suspected apnea, 497 whom were previously diabetes (treated diabetic patients), while 265 had no medical history but fasting blood ≥126 mg dL −1 and/or glycated haemoglobin (HbA 1c ) ≥6.5%...
Home non-invasive ventilation (NIV) is a widely used treatment for chronic hypoventilation but little known on its impact in the elderly. In multicenter prospective cohort study, we studied tolerance and efficacy of domiciliary NIV patients aged 75 or more compared to younger ones.264 with at least six-month follow-up were analyzed. Among them, 82 elderly younger, found an improvement arterial blood gas, Epworth sleepiness scale Pittsburgh sleep quality index 6 months. Mean daily use months...
Obstructive sleep apnea (OSA) and type 2 diabetes (T2D) are associated with endothelial dysfunction a main predictor of late cardiovascular (CV) events. Despite the high prevalence OSA in patients T2D, impact severity on function has not been clearly elucidated. The aim this cross-sectional study was to determine whether increasing is poorer T2D. 140 T2D no overt CV disease underwent polysomnography, peripheral arterial tonometry, clinic blood pressure (BP) measurement, biological assessment...
Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) cardiovascular disease (CVD). In 109 patients with severe OSA no overt CVD, biomarkers of (C reactive protein, interleukin-6, tumour necrosis factor-α its receptors, adiponectin, leptin P-selectin), glucose lipid metabolism, N-terminal pro-brain natriuretic peptide, were measured before after 2 months treatment a mandibular advancement device (MAD) (n=55) or sham (n=54). MAD reduced...